Source: Pharamceutical Technology

Replay: SY-104 by Syena for Multiple Myeloma (Kahler Disease): Likelihood of Approval

SY-104 is under clinical development by Syena and currently in Phase I for Multiple Myeloma (Kahler Disease).

Read full article »
Replay's Competitors | Replay's News | Replay's Financials
Stay up-to-date with the latest news on Replay
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Lachlan MacKinnon's photo - Co-Founder & CEO of Replay

Co-Founder & CEO

Lachlan MacKinnon

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Replay